Provided by Tiger Trade Technology Pte. Ltd.

Krystal Biotech Inc.

322.28
-3.0300-0.93%
Post-market: 322.280.00000.00%19:50 EDT
Volume:425.67K
Turnover:138.03M
Market Cap:9.54B
PE:40.46
High:329.22
Open:326.75
Low:320.29
Close:325.31
52wk High:382.54
52wk Low:179.16
Shares:29.60M
Float Shares:23.54M
Volume Ratio:1.75
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.97
EPS(LYR):6.84
ROE:20.12%
ROA:9.37%
PB:7.02
PE(LYR):47.12

Loading ...

Movement Alert|Krystal Biotech Inc. Falls 5.31% in Regular Trading, Q2 Revenue Misses Expectations Triggering Profit-Taking

Market Focus
·
Aug 03

Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Movement Alert|Krystal Biotech Inc. Falls 7.65% in Pre-Market Trading, Q2 Revenue Misses Market Expectations Despite EPS Beat

Market Focus
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength

Reuters
·
Aug 03

Krystal Biotech Shares Down 5.8% Premarket After Q2 Results

THOMSON REUTERS
·
Aug 03

Stock Track | Krystal Biotech Pre-market Plunge 5.61% as FY2026 Expense Guidance Overshadows Q2 Earnings

Stock Track
·
Aug 03

Krystal Biotech Q2 Net Income Rises 43% to $54.8 Million; Revenue Climbs 24% to $119.2 Million

Reuters
·
Aug 03

Earnings Flash (KRYS) Krystal Biotech Posts Q2 EPS $1.79, vs. FactSet Est of $1.62

MT Newswires Live
·
Aug 03

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

THOMSON REUTERS
·
Aug 03

Krystal Biotech - Sees FY 2026 Non-Gaap R&D and SG&a Expense $175 Mln-$195 Mln

THOMSON REUTERS
·
Aug 03

Krystal Biotech Q2 Product Revenue USD 119.222 Million

THOMSON REUTERS
·
Aug 03

Movement Alert|Krystal Biotech Inc. Rises 6.36% in Pre-Market Trading, Strong Q2 Earnings Expectations and S&P MidCap 400 Inclusion Drive Momentum

Market Focus
·
Jul 29

Earning Preview: Krystal Biotech Inc. Q2 revenue is expected to increase by 32.72%, and institutional views are bullish

Earnings Agent
·
Jul 27

Krystal Biotech Updates Financial Calendar with Quarterly Results Release, Conference Call

Reuters
·
Jul 24

Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?

Simply Wall St.
·
Jul 22

Krystal Biotech - Discontinues Clinical Study to Advance KB801 into Pivotal Trial; no Safety Concerns Observed - SEC Filing

THOMSON REUTERS
·
Jul 22

Krystal Biotech - no Further Subject-level Updates from Discontinued Study; Pivotal Trial Results Expected in Due Course - SEC Filing

THOMSON REUTERS
·
Jul 22

Krystal Biotech - Files Response with Uspto on KB801 Patent Application - SEC Filing

THOMSON REUTERS
·
Jul 22